Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 2;37(47):6933–6941. doi: 10.1016/j.vaccine.2019.02.040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — Total IgG titers elicited by intramuscular immunization with rH7 formulated with PELC/CpG combination adjuvant. (A) Groups of BALB/c mice were intramuscularly immunized with CHO-rH7 formulated with alum, R848, CpG, AddaVax, poly (I:C), or PELC/CpG adjuvant for two doses within a 3-week interval. Total IgG titers in sera were determined by ELISA for (B) 0.2 µg and (C) 2 µg CHO-rH7 antigen without or with alum, R848, CpG, AddaVax, poly (I:C), or PELC/CpG adjuvant. * indicates P < 0.05; ** indicates P < 0.01, ***, indicates P < 0.001.